- Barclays PLC BCS CEO, C.S. Venkatakrishnan, informed the Barclays Board and his colleagues that he would be undergoing treatment for Non-Hodgkin Lymphoma.
- Non-Hodgkin lymphoma is a type of cancer, meaning he would work from home for some time, CNBC reports.
- The CEO, known inside the bank as Venkat, said in a letter that his condition was curable and that doctors have said his prognosis is “excellent,” with the treatment in New York expected to last 12 to 16 weeks.
- “During this period, the company will run normally, and I will continue to be actively engaged in managing it,” Venkatakrishnan wrote.
- The bank confirmed that it had not appointed any interim CEO, with Venkat and the lender’s executive committee expected to continue running it.
- Non-Hodgkin lymphoma is cancer that develops in the lymphatic system, weakening the immune system. Still, most cases are considered “very treatable,” according to information on the website of Britain’s National Health Service.
- Price Action: BCS closed higher by 1.43% at $7.81 on Friday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.